Abcam plc – NASDAQ:ABCM
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Abcam stock price monthly change
+3.36%
month
Abcam stock price quarterly change
+4.81%
quarter
Abcam stock price yearly change
+48.73%
year
Abcam key metrics
Market Cap | 5.52B |
Enterprise value | 2.84B |
P/E | -262.6 |
EV/Sales | 10.94 |
EV/EBITDA | 71.50 |
Price/Sales | 7.65 |
Price/Book | 2.73 |
PEG ratio | -8.75 |
EPS | N/A |
Revenue | 458.15M |
EBITDA | 52.4M |
Income | 275K |
Revenue Q/Q | 9.71% |
Revenue Y/Y | 18.01% |
Profit margin | 4.81% |
Oper. margin | 4.04% |
Gross margin | 69.31% |
EBIT margin | 4.04% |
EBITDA margin | 11.44% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAbcam stock price history
Abcam stock forecast
Abcam financial statements
| Sep 2022 | 88.25M | -7.15M | -8.1% |
|---|---|---|---|
| Dec 2022 | 166.7M | -9.37M | -5.62% |
| Mar 2023 | 101.6M | 8.4M | 8.27% |
| Jun 2023 | 101.6M | 8.4M | 8.27% |
| 2025 | 518.75M | 110.56M | 21.31% |
|---|
Analysts Price target
Financials & Ratios estimates
0%
Yield TTM
| Payout ratio | 0% |
|---|
| 2017 | 0.96% |
|---|---|
| 2019 | 0.84% |
| 2020 | 0.9% |
| 2021 | 0.63% |
| 2022 | 0.85% |
| Sep 2022 | 1056599999 | 201.8M | 19.1% |
|---|---|---|---|
| Dec 2022 | 1056600000 | 329.7M | 31.2% |
| Mar 2023 | 1027099999 | 307.9M | 29.98% |
| Jun 2023 | 1027100000 | 307.9M | 29.98% |
| Sep 2022 | -550K | -5.25M | -4.09M |
|---|---|---|---|
| Dec 2022 | -550K | -5.25M | -4.09M |
| Mar 2023 | 13.65M | -10.5M | -5.9M |
| Jun 2023 | 13.65M | -10.5M | -5.9M |
Abcam alternative data
| Aug 2023 | 1,760 |
|---|---|
| Sep 2023 | 1,760 |
| Oct 2023 | 1,760 |
| Nov 2023 | 1,760 |
| Dec 2023 | 1,760 |
| Jan 2024 | 1,760 |
| Feb 2024 | 1,760 |
| Mar 2024 | 1,760 |
| Apr 2024 | 1,760 |
| May 2024 | 1,760 |
| Jun 2024 | 1,760 |
| Jul 2024 | 1,760 |
Abcam other data
39.77%
-38.36%
of ABCM is owned by hedge funds
93
-30
91.98M
-86.86M
shares is hold by hedge funds
| Quarter | Transcript |
|---|---|
| Q4 2022 12 Sep 2022 | Q4 2022 Earnings Call Transcript |
| Q4 2021 14 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Alan Thomas Hirzel BS, MS, MBA (1968) Chief Executive Officer & Executive Director | $1,420,000 |
Mr. Michael Shaun Baldock (1964) Chief Financial Officer & Director | $712,860 |
-
When is Abcam's next earnings date?
Unfortunately, Abcam's (ABCM) next earnings date is currently unknown.
-
Does Abcam pay dividends?
No, Abcam does not pay dividends.
-
How much money does Abcam make?
Abcam has a market capitalization of 5.52B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 14.68% to 361.7M US dollars.
-
What is Abcam's stock symbol?
Abcam plc is traded on the NASDAQ under the ticker symbol "ABCM".
-
What is Abcam's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Abcam?
Shares of Abcam can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Abcam's key executives?
Abcam's management team includes the following people:
- Mr. Alan Thomas Hirzel BS, MS, MBA Chief Executive Officer & Executive Director(age: 57, pay: $1,420,000)
- Mr. Michael Shaun Baldock Chief Financial Officer & Director(age: 61, pay: $712,860)
-
How many employees does Abcam have?
As Jul 2024, Abcam employs 1,760 workers.
-
When Abcam went public?
Abcam plc is publicly traded company for more then 4 years since IPO on 22 Oct 2020.
-
What is Abcam's official website?
The official website for Abcam is abcam.com.
-
How can i contact Abcam?
Abcam can be reached via phone at +44 1223 696000.
Abcam company profile:
Abcam plc
abcam.comExchange:
NASDAQ
Full time employees:
1,760
Industry:
Biotechnology
Sector:
Healthcare
Abcam plc, a life science company, focuses on identifying, developing, and distributing reagents and tools for scientific research, diagnostics, and drug discovery. Its principal products include primary and secondary antibodies; conjugated antibodies and conjugation kits; singleplex and multiplex immunoassays; proteins and peptides that include cytokines; edited cell lines and lysates; and various other products, including cellular activity kits, miRNA kits, biochemicals, and cell signaling pathway tools. The company serves scientists and researchers in academic institutions and research institutes, as well as in pharmaceutical, biotechnology, and diagnostics companies. It has operations in the Americas, Europe, the Middle East, Africa, China, Japan, and rest of the Asia Pacific. The company sells its products online. Abcam plc was incorporated in 1998 and is headquartered in Cambridge, the United Kingdom.
Discovery Drive
Cambridge, CB2 0AX
Cambridge, CB2 0AX
CIK: 0001492074
ISIN: US0003802040
CUSIP: 000380204
